Eon Labs Receives Final Approval for Bupropion HCl, ER 200mg Tablets and Will Begin Shipping Immediately

Eon Labs, Inc. (Nasdaq: ELAB) announced today that it
received final approval for Bupropion HCl, ER 200mg tablets, the
generic equivalent of Wellbutrin SR(R)* 200mg tablets. The Company
will begin shipping immediately.
   Eon Labs is a generic pharmaceutical company specializing in
developing, licensing, manufacturing, selling and distributing a broad
range of prescription pharmaceutical products. For press releases and
other company information, visit the Eon Labs, Inc. website at
www.eonlabs.com.

   Safe Harbor Statement under the U.S. Private Securities Litigation
Reform Act of 1995: This release contains statements that are
forward-looking in nature which express the beliefs and expectations
of management. Such statements are based on current plans, estimates
and expectations and involve a number of known and unknown risks,
uncertainties and other factors that could cause the Company's future
results, performance or achievements to differ significantly from the
results, performance or achievements expressed or implied by such
forward-looking statements. These factors and additional information
are discussed in the Company's filings with the Securities and
Exchange Commission and statements in this release should be evaluated
in light of these important factors. Although we believe that these
statements are based upon reasonable assumptions, we cannot guarantee
future results. Forward-looking statements speak only as of the date
on which they are made, and the Company undertakes no obligation to
update publicly or revise any forward-looking statement, whether as a
result of new information, future developments or otherwise.

   * Wellbutrin SR(R) is a registered trademark of GlaxoSmithKline
and is not affiliated with Eon Labs, Inc.